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Abstract
Background: It has been shown in experimental and theoretical work that covalently modified signaling cascades
naturally exhibit bidirectional signal propagation via a phenomenon known as retroactivity. An important
consequence of retroactivity, which arises due to enzyme sequestration in covalently modified signaling cascades,
is that a downstream perturbation can produce a response in a component upstream of the perturbation without
the need for explicit feedback connections. Retroactivity may, therefore, play an important role in the cellular
response to a targeted therapy. Kinase inhibitors are a class of targeted therapies designed to interfere with a
specific kinase molecule in a dysregulated signaling pathway. While extremely promising as anti-cancer agents,
kinase inhibitors may produce undesirable off-target effects by non-specific interactions or pathway cross-talk. We
hypothesize that targeted therapies such as kinase inhibitors can produce off-target effects as a consequence of
retroactivity alone.
Results: We used a computational model and a series of simple signaling motifs to test the hypothesis. Our results
indicate that within physiologically and therapeutically relevant ranges for all parameters, a targeted inhibitor can
naturally induce an off-target effect via retroactivity. The kinetics governing covalent modification cycles in a
signaling network were more important for propagating an upstream off-target effect in our models than the
kinetics governing the targeted therapy itself. Our results also reveal the surprising and crucial result that kinase
inhibitors have the capacity to turn “on” an otherwise “off” parallel cascade when two cascades share an upstream
activator.
Conclusions: A proper and detailed characterization of a pathway’s structure is important for identifying the
optimal protein to target as well as what concentration of the targeted therapy is required to modulate the
pathway in a safe and effective manner. We believe our results support the position that such characterizations
should consider retroactivity as a robust potential source of off-target effects induced by kinase inhibitors and
other targeted therapies.
Background
Cells propagate information through protein signaling
pathways that are part of complex signal transduction
networks [1]. The simplest view of cellular signaling
entails a cascade of molecular events initiated by the
recognition of a stimulus and culminating in the chemi-
cal alteration of an effector molecule. In the case of
covalent modification by the addition or removal of a
phosphate group, a reaction commonly found in
signaling cascades, each phosphorylated protein serves
as the kinase that activates the next cycle’s unpho-
sphorylated protein.
Targeted therapies are used to modulate disease pro-
gression by inhibiting a specific protein within a dysre-
gulated signaling pathway [2]. Kinase inhibitors are a
class of targeted therapies designed to interfere with a
specific kinase molecule. While extremely promising as
anti-cancer agents, kinase inhibitors can produce off-tar-
get effects by inducing changes in molecules other than
the one specifically targeted. Such off-target effects are
generally attributed to non-specific binding or to cross-
talk [3].
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Recent theoretical and experimental studies have
demonstrated that covalently modified cascades also
exhibit bidirectional signal propagation via a phenom-
enon termed retroactivity [4-9]. This phenomenon arises
because cycles in a cascade are coupled, not only to the
next cycle, but also to the previous cycle (Figure 1). The
cycles can be thought of as modules where each mod-
ule’s substrate sequesters a key component of the pre-
vious module, limiting the component’s ability to
participate in the previous module and inducing a nat-
ural change in the preceding module. This change may
then propagate upstream through one or more preced-
ing modules.
While retroactivity is naturally present in covalently
modified cascades, signaling pathways likely have
evolved to propagate signals in an optimized down-
stream manner. An important consequence of retroac-
tivity, however, is that a downstream perturbation in a
signaling cascade can produce an upstream effect with-
out the need for explicit negative feedback connections
[4]. Retroactivity may, therefore, play important roles in
the dysregulated signaling networks of diseased cells as
well as the cellular response to targeted therapies
applied to dysregulated signaling networks.
Ventura, Sepulchre, and Merajver [4] demonstrated
that increasing the concentration of the inactivating
enzyme (e.g., a phosphatase) in the terminal cycle of a
cascade can decrease the concentration of the activated
protein in the previous cycle [4]. This finding led us to
hypothesize that a targeted inhibitor can produce
upstream off-target effects via retroactivity that can pro-
pagate elsewhere in the signaling network.
Off-target effects associated with targeted therapies are
often attributed to crosstalk, which refers to inter-path-
way molecular interactions arising because of explicit
regulatory feedback connections between two pathways
Figure 1 Retroactivity arises due to enzyme sequestration in covalently modified cascades. A simple signaling cascade is depicted where
each sequential cycle represents the activation (denoted by *) and inactivation of protein Yi. Y1* serves as the activating enzyme of Y2 and Y2*
serves as the activating enzyme of Y3. The cycles can be thought of as modules where each module’s substrate sequesters a key component of
the previous module, limiting the component’s ability to participate in the previous module. This sequestration induces a natural change in the
preceding module which may propagate upstream through one or more preceding modules. In this example, a perturbation in the deactivation
reaction of cycle 3 induces an effect in cycle 2. If the perturbation takes the form of an increase in the concentration or activity of the enzyme
catalyzing the conversion of Y3* to Y3, more Y3 will be available to react with and sequester Y2*, resulting in less Y2 substrate availability for the
reaction with Y1*. Thus, a reverse response can propagate upstream to a preceding cycle or cycles. In the schematic, black arrows represent the
cell surface to nucleus direction of cellular signaling and red arrows represent the direction of retroactive signaling.
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or because two pathways share one or more molecular
components. It is well accepted that two pathways shar-
ing one or more components can exhibit cross-talk with
respect to a stimulation or perturbation above the
shared component(s). If an upstream perturbation
occurs in one of the pathways, the perturbation may
affect the other pathway via the shared downstream
component(s). Such a scenario could lead to specificity
problems [10]. Here we propose that perturbations (e.g.,
from an inhibitor) that occur downstream of a shared
component can also induce cross-talk effects without
any explicit feedback connections via the following
mechanism: the information travels upstream from the
site of the perturbation through retroactivity, reaches
the common component and then is delivered to the
parallel pathway.
To test our hypothesis, we created a computational
model that tested the application of a kinase inhibitor in
a series of simple signaling networks. The objective of
the model was to probe the effect of a targeted inhibitor
on retroactive signaling and to test whether retroactivity
is likely to contribute to measurable off-target effects
under physiological conditions. Specifically, the model
simulated the targeted inhibition of a specific kinase in
a series of multi-cycle networks. In all networks, at least
two cascades were activated by the same upstream cycle
with no explicit feedback connections between them.
Our results indicate that within physiologically and
therapeutically relevant ranges for all parameters, a tar-
geted inhibitor can naturally induce a steady state off-
target effect via retroactivity. Our results also reveal the
surprising and crucial result that a downstream kinase
inhibitor has the capacity to turn “on” an otherwise “off”
parallel cascade when two cascades share an upstream
activator.
Methods
Model development
We designed simple signaling networks to test whether
a measurable off-target effect in one cascade can occur
when a protein in another cascade is selectively inhib-
ited. In each network studied, cycle i contained the
active (phosphorylated) and inactive (unphosphorylated)
forms of protein Yi, where the active form was denoted
by Y∗i . For simplicity, we refer to activating and inacti-
vating enzymes in a network as kinases and phospha-
tases, respectively.
Protein Y1* served as the activating kinase for all cas-
cades. Cycle 2 and cycle n were always in distinct cas-
cades (Figure 2). To determine if an off-target effect
occurred due to perturbation by the inhibitor, the steady
state concentration of the protein in cycle 2 was moni-
tored as the concentration of the drug that specifically
targeted Yn* was increased. A competitive inhibitor was
used that directly bound to Yn*, limiting its ability to
participate in the phosphatase reaction of cycle n, but
Figure 2 Topology of signaling networks studied. Two general types of network motifs consisting of covalently modified cycles were
studied: (A) the vertical case where the n-th cycle in the right hand cascade is inhibited and (B) the lateral case where the n-th single-cycle
cascade is inhibited. (C) The n = 3 network consisted of exactly 3 cycles and was the simplest form of both the vertical and lateral case. (D) An
extended n = 3 network was also studied where a fourth cycle activated by Y2* was added to the left-most cascade. In all networks, Y1* served
as the upstream activator and cycle 2 and cycle 3 were always in distinct cascades. No additional regulatory connections were included in any
network. Off-target effects in cycle 2 were monitored by measuring the steady state concentrations of Y2 and Y2* as the concentration of an
inhibitory drug that specifically targeted Yn* was increased.
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did not change the rate of the phosphatase reaction in
cycle n.
Two general network types were considered: a vertical
and a lateral case (Figure 2). The vertical case consisted
of two cascades where the inhibited cascade length var-
ied (Figure 2A). This motif is similar to the upstream
activation of JUN and P53 by JNK1/2 in the mitogen-
activated protein kinase (MAPK) pathway [11]. The lat-
eral case was equivalent to a fan-out network topology
and consisted of n - 1 single cycle cascades that were all
activated by Y1* (Figure 2B). This motif is similar to the
activation of multiple cascades by p38 [11]. The n = 3
network consisted of exactly 3 cycles and represented
the simplest form of both network types studied (Figure
2C).
The general reaction scheme used for the vertical, lat-
eral, and n = 3 networks was:
Yi + Eki
ai←→
di
Ci
ki−→ Y∗i + Eki
Y∗i + Epi
a′ i←→
d′′ i
C′i
ki−→ Yi + Epi
Y∗n +D
kon←→
koff
CD
Where
Eki =
⎧⎪⎪⎨
⎪⎪⎩
i = 1,
i = 2, i = 3,
i > 3 (vertical),
i > 3 (lateral),
Ek1
Y∗1
Y∗i−1
Y∗1
Y∗i is the activated protein in the i
th cycle
Yi is the inactivated protein in the i
th cycle
Eki is the kinase enzyme in the i
th cycle
Epi is the phosphatase enzyme in the i
th cycle
D is the inhibitory drug
Ci is the Yi and Ekicomplex in the i
th cycle
C′i is the Y
∗
i and Epi complex in the i
th cycle
CD is the Y
∗
n and D complex in the n
th cycle
Parameter definitions
In order to reduce the complexity of each network stu-
died, parameters were non-dimensionalized into 4 para-
meter types as described in Appendix A. The allowed
value of each parameter type was restricted to the
default ranges listed in Table 1. A summary of the para-
meter types is provided below.
Subscripts containing k or p indicate parameters asso-
ciated with a kinase or phosphatase reaction, respec-
tively, and subscripts containing T indicate the total
concentration of a species. Vmax and Km are the stan-
dard Michaelis-Menten constants representing, respec-
tively, the maximum velocity of a reaction (at a given
enzyme concentration) and the substrate concentration
necessary to achieve 12Vmax[12].
(1) total enzyme to substrate ratio of the kinase and
phosphatase reaction, respectively, in cycle i:
Ei = EkiT /YiT E
′
i = EpiT /YiT
(2) normalized Km of the kinase and phosphataste
reaction, respectively, in cycle i:
K i = Kmki /YiT K
′
i = Kmpi /YiT
where Kmki =
di + ki
ai
and Kmpi =
d′i + k′i
a′i
(3) Vmax ratio of the kinase and phosphatase reac-
tions in cycle i:
Pi = Vmaxki /Vmaxpi
Table 1 The parameter space of each network consisted of a set of non-dimensional parameters, each with a
minimum and maximum allowed value.
default range
parameter minimum maximum description
Ei 0.01 100 total kinase to total substrate ratio
E’i 0.01 100 total phosphatase to total substrate ratio
Ki 0.01 100 normalized Km of kinase reaction
K’i 0.01 100 normalized Km of phosphatase reaction
Pi 0.1 10 ratio of the kinase reaction Vmax to the phosphatase reaction Vmax
KB 0.01 100 normalized drug disassociation constant
Each cycle i consisted of 5 dimensionless parameters: Ei, E’i, Ki, K’i, and Pi. A final parameter, KB, applied to the targeted inhibitor. Randomly selected
dimensionless parameter values could not exceed the default ranges listed for each parameter type.
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where Vmaxki = kiEkiT and Vmaxpi = k
′
iEpiT
(4) normalized disassociation constant of the inhibi-
tor binding to Yn*:
KB =
koff /kon
YnT
Ei and E’i values less than 1 indicate that the enzyme
is less abundant than the substrate. Ki and K’i values
less than 1 indicate that the total available substrate
exceeds the concentration needed to reach Km and,
consequently, the enzymatic reaction operates close to
or in the zero order regime [13]. In contrast, Ki and
K’i values greater than 1 indicate that an insufficient
amount of substrate exists to reach Km and the enzy-
matic reaction operates in the linear regime [13]. Pi
values greater than 1 indicate that the Vmax of the
kinase reaction exceeds the Vmax of the phosphatase
reaction and, consequently, the cycle tends toward the
activation reaction. Likewise, Pi values less than 1 indi-
cate that the cycle tends toward the deactivation
reaction.
Determination of off-target effects
The concentrations of species Yi, Y
∗
i , and the inhibitory
drug D were normalized as follows:
yi =
[Yi]
YiT
y∗i =
[Y∗i ]
YiT
I =
DT
YnT
To determine if a detectable off-target effect
occurred for a specific set of parameters, changes in
the steady values of y2 and y
∗
2 were monitored as the
model parameters were held fixed but I was varied
from 10-4 to 104. If a change in the steady state value
of y2 or y
∗
2 occurred that was greater than or equal to
a detection threshold of 0.10 (i.e., 10% of the total
protein in cycle 2), an off-target effect in cycle 2 was
reported. For numeric reasons, the range used for I
was intentionally larger than needed. For a given
parameter set, it was numerically more efficient to
simulate with a small (10-4) and a large (104) value
for I and then check for a change in the steady state
values of y2 and y
∗
2 than it was to simulate with many
values of I. In fact, the majority of off-target effects in
our model were observed as I was varied from 0.1 to
10.
When we tested the n = 3 network, we obtained the
same results when we used either I = 0.0000 or I =
0.0001 (10-4) as the minimum drug concentration. For
this reason (and because it would be experimentally
challenging to distinguish 0.0000 from 0.0001 in vivo),
we effectively considered I = 10-4 to represent the
absence of the drug in the system.
Numerical simulations
For each network tested, a system of ordinary differen-
tial equations (ODEs) was used to model the rate of
change of the reactants. Because we were only interested
in changes in steady state values as a function of I, we
first solved the system by setting the ODEs equal to
zero and generating a system of steady state equations.
As described in Appendix A, the model in this form was
the basis for the non-dimensionalization of model
parameters.
For numerical reasons, it was more efficient to solve
the ODEs over a very long time period rather than sol-
ving the system of steady state equations directly. After
randomly selecting a set of non-dimensional parameters,
the selected values were mapped to corresponding
dimensional parameter values (Additional File 1) and
the system of ODEs was solved using the Matlab
R2009b ode15s stiff solver from 0 to a maximum of
100,000 arbitrary time units. The majority (~90%) of
randomly selected parameter sets obtained steady state
within 5,000 arbitrary time units. The units are arbitrary
because we began with dimensionless parameters lack-
ing an explicit timescale. Finally, to confirm the numeri-
cal steady state solution, the original dimensionless
parameters and the final yi and yi* variable values were
substituted into the analytical steady state equations
listed in Appendix A. Matlab source code was compiled
as a C program and run on Intel Nehalem/i7 Core
processors.
Random parameter space exploration
Random parameter selection was performed via latin
hypercube sampling (LHS) to provide an efficient and
even sampling distribution across the range of allowed
values in the parameter space [14-16]. Each parameter
space exploration consisted of 5000 randomly selected
parameter sets. The number of parameter sets sampled
was determined by calculating the percent of off-target
effects in q randomly sampled parameter sets for the n
= 3 network (Figure 2C). The variation in the percent of
off-target effects stabilized when q was greater than or
equal to 5000 (Additional File 2 Figure S1). The percen-
tage of 5000 randomly selected parameter sets that pro-
duced an off-target effect provided a probability that
off-target effects would occur in a given network’s para-
meter space.
Numeric perturbation analysis
A modified perturbation method was used to probe
which model parameters were most important for pro-
ducing an off-target effect as a result of the inhibition of
Yn*. Traditional biochemical sensitivity analysis [17]
with the dimensionless parameters was not possible
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because these parameters applied to the steady state
equations and not the time dependent differential equa-
tions (Appendix A). Instead, we developed a numerical
perturbation based method that allowed us to evaluate
the parametric sensitivity of off-target effects in a net-
work’s parameter space. In the method, the value of a
single parameter was randomly selected from a
restricted range of values while all other parameter
values were randomly selected from the full range per-
mitted by the baseline parameter space. If off-target
effects are sensitive to a given parameter, we expect that
when values for the parameter under test are randomly
selected from a reduced range of values, the percentage
of off-target effects produced will differ from the per-
centage produced when values for the parameter are
instead selected from a fixed baseline range. In both
cases, all other parameter values are selected from a
fixed baseline range so that the only change in the sys-
tem is a perturbation in the allowed range of the para-
meter under test.
The reduced ranges used to perturb each parameter
were arrived at by partitioning the default range estab-
lished for each parameter type in Table 1. The default
ranges were divided into smaller perturbation sub-
ranges such that the minimum and maximum of a sub-
range was an order of magnitude larger than the mini-
mum and maximum of the previous sub-range. Because
the Ei, E’i, Ki, K’i, and KB parameters had a default
initial range of 0.01 - 100.0 (Table 1), the sub-ranges
used to perturb these parameters were: (i) 0.01 - 0.10,
(ii) 0.10 - 1.0, (iii) 1.0 - 10.0, and (iv) 10.0 - 100.0.
Because the Pi parameters had a default range of 0.10 -
10.0, the sub-ranges used to perturb these parameters
were: (i) 0.10 - 1.0 and (ii) 1.0 - 10.0.
A complete numeric perturbation analysis of a para-
meter space consisted of determining the percentage of
off-target effects in 5000 randomly selected parameter
sets for each parameter’s sub-ranges. In the n = 3 net-
work (Figure 2C) there were a total of 16 parameters (5
parameters per cycle and KB). Three of the parameters
(P1, P2, and P3) had 2 perturbation sub-ranges each and
the remaining 13 parameters had 4 perturbation sub-
ranges each. In this example, the analysis consisted of a
total of 59 sets of 5000 simulations (58 sets for each
parameter sub-range and 1 set to establish the baseline
percentage of off-target effects in the parameter space
prior to perturbation).
Results
The question we wanted to answer with our models was
whether a targeted inhibitor is likely to induce a mea-
surable off-target effect due to retroactivity in a non-tar-
geted cascade under physiological conditions. In each
network, cycle n, was perturbed by an inhibitor. An off-
target effect occurred in the model if, after increasing I
(the normalized inhibitor concentration) from 10-4 to
104, a change in the steady state concentration of Y2
and/or Y2* occurred that was at least 0.10 of the total
Y2 protein pool. For example, a change of 0.25 in Y2
and 0.08 in Y2* would indicate that the steady state
values of Y2 and Y2* changed by 25% and 8% of the
total Y2 protein pool, respectively, and that a detectable
off-target effect occurred in Y2.
Specific parameter ranges promote off-target effects in
cycle 2
First, we investigated the n = 3 network (Figure 2C)
where Y3* is targeted by the inhibitor. When the full
parameter space (defined in Table 1 and depicted in Fig-
ure 3H) was used, 1.6% of the 5000 randomly selected
parameters sets produced an off-target effect in cycle 2.
This value was essentially unchanged (1.5%) when we
randomly selected 50,000 parameter sets for comparison
(Additional File 2). To identify the model parameters
that were most important for producing a cycle 2 off-
target effect, a numeric perturbation analysis was per-
formed (Figure 3A-F). The results of the analysis suggest
that the parameters controlling the activity of cycle 3
play a large role in inducing an off-target effect in cycle
2. Not surprisingly, K3 (the normalized Km of the kinase
reaction in cycle 3) had the greatest effect on off-target
effects in this network (Figure 3D). K3 determines how
much sequestration of Y1* by Y3 occurs and this is the
key mechanism of retroactivity. When K3 was restricted
to values greater than 1, the off-target effects in the net-
work were essentially eliminated. In contrast, when K3
was restricted to values between 0.01 and 0.10, the per-
centage of off-target effects increased to 4.6%. Similarly,
K’3 (the normalized Km of the phosphatase reaction in
cycle 3) also affected the percentage of off-target effects
but to a lesser degree than K3 (Figure 3E).
E3 and E’3 (the total kinase to substrate and the total
phosphatase to substrate ratio, respectively, in cycle 3)
also appeared to exert a large degree of control over off-
target effects (Figure 3A-B). These results indicate that
off-target effects were more likely when the kinase and
phosphatase enzymes of cycle 3 were saturated. P3, the
ratio of the Vmax of the kinase and phosphatase reac-
tions in cycle 3, also affected the percentage of off-target
effects (Figure 3C). When P3 was less than 1, cycle 3
tended toward the deactivation reaction and the percen-
tage of off-target effects increased to 2.56% from 1.6%.
Similarly, when P3 was greater than 1, cycle 3 tended
toward the activation reaction and the percentage of off-
target effects was significantly reduced relative to the
baseline (0.32%).
The only parameter associated with cycle 2 that
affected the percentage of off-target effects in this
Wynn et al. BMC Systems Biology 2011, 5:156
http://www.biomedcentral.com/1752-0509/5/156
Page 6 of 15
network was K2 (the normalized Km of the kinase reac-
tion of cycle 2). K2 values between 0.01 and 0.10 are
expected to produce an efficient kinase reaction
because Y2T >> Km2. The results of the numerical per-
turbation analysis indicated that when K2 was
restricted to values in this sub-range, a small percen-
tage of off-target effects was observed (Figure 3D). In
contrast, when K2 was restricted to values between 1.0
and 10.00, the percentage of off-target effects increased
relative to the baseline. These results suggest that an
off-target effect in cycle 2 is more likely to occur in
the n = 3 network when the conversion of Y2 to Y2*
operates in the linear regime because of substrate
constraints. This result is somewhat counter intuitive
given the fact that we are interested in measuring a
response that propagates from cycle 3 to cycle 1 and
then down to cycle 2. It is reasonable to expect that an
efficient kinase reaction in cycle 2 would be important
for recruiting Y1* to activate Y2 and generate an effect
in cycle 2. If the cycle 2 kinase reaction is less efficient
than the cycle 3 kinase reaction, however, more Y1*
will be available to convert Y3 to Y3*, ultimately contri-
buting to the sequestration of more Y3* into a complex
with D. Such a sequestration may give rise to a detect-
able upstream effect as a result of the reduced sub-
strate availability in cycle 3.
Figure 3 A numeric perturbation analysis revealed parameter value ranges that promote off-target effects in the n = 3 network. A
perturbation analysis of the n = 3 network (G) was performed where a single parameter’s value was randomly selected from a small range of
values, while all other parameters were selected from the larger ranges defined in Table 1. The baseline in each plot reflects the percent of off-
target effects in cycle 2 in 5000 sampled parameter sets when all parameter values were randomly selected from the ranges defined in Table 1
and depicted in (H). All other bars reflect the results of systematically perturbing each parameter (one at a time) using the given sub-ranges (A-
F). Based on this perturbation analysis, a restricted parameter space was generated (I) from which ~74% of the sampled parameter sets
produced off-target effects in cycle 2. In contrast, only ~1.6% of sampled parameter sets from the full parameter space (H) produced off-target
effects in cycle 2.
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The cycle 1 parameters with the greatest impact on
the percentage of off-target effects were K1 and K’1 (the
normalized Km of the kinase and phosphatase reaction,
respectively, in cycle 1) (Figure 3D-E). Larger values of
K1 acted to suppress off-target effects, while smaller
values produced an increase in off-target effects relative
to the baseline (Figure 3D). The reverse was observed
for K’1, with higher values producing a higher percen-
tage of off-target effects than smaller values (Figure 3E).
Together, the K1 and K’1 results suggest that off-target
effects are favored when the cycle 1 phosphatase reac-
tion tends toward inefficiency and the cycle 1 kinase
reaction tends towards efficiency. This result is not sur-
prising given that the availability of Y1* is essential for
the propagation of a signal from cycle 3 to cycle 2.
The value of KB, the normalized drug disassociation
constant, had a very slight effect on the percentage of off-
target effects. In general, KB values greater than 1 pro-
duced a slight decrease in the percentage of off-target
effects relative to the baseline (Figure 3F). This result
suggests that weaker binding (and larger dissociation
constants) promoted fewer off-target effects, as would be
expected given the decreased sequestration of Y3* that
would occur. The change in the percentage of off-target
effects induced by restricting KB values was fairly small
compared to the change induced when other model para-
meter values were restricted. This result suggests that the
activity and efficiency of component cycles in the net-
work may be more important for propagating an off-tar-
get effect than the actual kinetics of a targeted therapy.
The results of the above analysis indicate that certain
parameter value ranges are more likely to induce an off-
target effect in cycle 2 as the drug concentration is
increased. When we restricted the n = 3 parameter
space by reducing the ranges from which some key
parameters were selected (Figure 3I), the percentage of
off-target effects in 5000 randomly sampled parameter
sets increased from 1.6% to 73.9%.
A second numerical perturbation analysis was per-
formed using this new restricted n = 3 parameter space
as a baseline. In general, many of the trends observed in
the analysis of the original n = 3 parameter space
(depicted in Figure 3H) were observed in the analysis of
the restricted n = 3 parameter space (Additional File 3
Figure S3). For example, low K3 values remained impor-
tant for producing off-target effects in both parameter
spaces. The effects of parameters associated with cycle
2, however, were different in the two parameter spaces.
When the original parameter space was tested, K2 was
the only cycle 2 parameter found to substantially affect
the percentage of off-target effects (Figure 3D). In the
restricted parameter space, however, some ranges of E2,
E’2, and K’2 produced off-target effect percentages that
differed substantially from the baseline. For example, E2
values between 10 and 100 produced off-target effects in
92.1% of sampled parameter sets, the largest percentage
of off-target effects observed in any of our analyses
(Additional File 3 Figure S3A). Because E2 is the total
enzyme to substrate ratio of the kinase reaction (Y1T/
Y2T), this result suggests when more total protein exists
in cycle 1 compared to cycle 2, off-target effects in cycle
2 are more likely in this network.
While some parameters associated with cycle 2 were
able to effect the percentage of off-target effects, the
parameters associated with cycle 3 continued to have
the greatest effect on off-target effects in the restricted n
= 3 parameter space. Only parameters in cycle 3 had the
ability to effectively eliminate (or substantially reduce)
the percentage of off-target effects within specific
reduced ranges. Values between 10 and 100 for E3, E’3,
K3 and K’3 produced off-target effect percentages of 0%,
3.24%, 0% and 3.20%, respectively. In addition, P3 values
greater than 1 produced off-target effects in 18.24% of
sampled parameter sets which, compared to the baseline
of 73.9%, represents a large decrease in off-target effects
(Additional File 3 Figure S3).
Varying a single parameter can produce a large change
in the size of the off-target effect
The magnitude of off-target effects produced by para-
meter sets randomly sampled from the original n = 3
parameter space (depicted in Figure 3H) generally fell
between .10 and .30 of the total Y2 protein pool (Figure
4A). In contrast, the magnitude of off-target effects pro-
duced by parameter sets randomly sampled from the
restricted n = 3 parameter space (depicted in Figure 3I)
were more uniformly distributed across a range of
values (Figure 4B). These results suggest that when con-
ditions in a network are favorable for off-target effects,
the size of an off-target effect is highly variable.
We used stimulus response curves to examine how a
change in a single parameter value may affect the size of
an off-target effect in Y2* as a function of the normal-
ized inhibitor concentration (Figure 5). A randomly
selected parameter set and a parameter set derived from
a Xenopus MAPK model [18] were used (refer to Addi-
tional File 4 for the derivation of the Xenopus parameter
values). In each parameter set, either E2 or K3 was var-
ied, while all other parameter values were fixed to the
values listed in Table 2.
The randomly selected parameter set produced a base-
line off-target response of 0.19 in Y2* (Figure 5A-B) and
of 0.40 in Y2 (data not shown). In this parameter set the
original E2 value was 32.56 and the original K3 value
was 0.04 (Table 2). Increasing E2 to 326.61 substantially
decreased the response in Y2* and decreasing E2 to 3.26
increased the response in Y2* from 0.19 to 0.27 (Figure
5A). Similarly, increasing K3 to 0.41 reduced the
Wynn et al. BMC Systems Biology 2011, 5:156
http://www.biomedcentral.com/1752-0509/5/156
Page 8 of 15
response in Y2* to 0.07 (below the detection threshold)
and decreasing K3 to 0.004 increased the response in
Y2* to 0.26 (Figure 5B).
The parameter set derived from the MAPK Xenopus
model [18] produced a baseline response of 0.08 (below
the detection threshold) in both Y2* (Figure 5C-D) and
Y2 (data not shown). In this parameter set the original
E2 value was 0.0025 and the original K3 value was 0.25
(Table 2). While changing E2 did not alter the response
(Figure 5C), increasing K3 to 2.5 completely eliminated
the response in Y2* and decreasing K3 to 0.025 substan-
tially increased the response in Y2* to 0.60 (Figure 5D).
These results suggest that when using physiologically
realistic parameter values, changing one kinetic para-
meter or species concentration by an order of magni-
tude has the capacity to dramatically alter whether a
targeted inhibitor induces an off-target effect.
A few of the enzyme to substrate ratios in the Xenopus
parameter set (E2 = 0.0025, E’2 = 0.00025, and E3 =
0.0025) were outside the limits of parameter ranges
allowed in our random parameter space explorations
(Table 1 and Figure 3H), suggesting that off-target effects
are possible for a larger range of parameter values than
we specifically tested. While we may have been too con-
servative in the estimation of the ranges defined in Table
1, this finding supports the position that a targeted inhi-
bitor can naturally induce an off-target effect via retroac-
tivity over a range of physiologically relevant conditions.
The percentage of off-target effects decreased as the size
of the vertical and lateral networks increased
We next investigated networks with more than 3 cycles
by randomly exploring the parameter spaces of the
vertical (Figure 2A) and lateral (Figure 2B) cases using n
= 5 and n = 7 cycles. As before, we measured the steady
state change in cycle 2 as the normalized concentration
of the drug that targeted cycle n was increased. The
restricted parameter space depicted in Figure 3I (from
which 73.9% of sampled parameter sets produced off-
target effects in cycle 2) was used for this analysis. Net-
works were analyzed using homogenous parameter
values in cycles 4, 5, 6 and 7 that equalled the corre-
sponding parameter values randomly selected for cycle 3
(e.g., in the n = 5 case, E3 = E4 = E5). This allowed us
to keep the size of the parameter space fixed so that
5000 parameter sets remained a reasonable number to
sample from each network’s parameter space.
In the vertical case, the percentage of off-target effects
in the n = 5 and n = 7 networks were 27.92% and
13.50%, respectively (Table 3). The reduced probability
of off-target effects as the cascade lengthened suggests
that applying a targeted inhibitor near the bottom of a
long cascade can produce a detectable off-target
response but the signal may attenuate as it travels up
the cascade. This conclusion is in agreement with a
recent work that investigated retroactivity in long signal-
ing cascades [9] and found that retroactive signals are
likely to attenuate as they travel up long cascades.
In the lateral case, the drop in the percentage of off-
target effects was more dramatic than in the vertical
case, with the n = 5 and n = 7 networks producing 6%
and 0% off-target effects, respectively (Table 3). This
result suggests applying a targeted inhibitor to a cycle
that is activated by a signaling molecule involved in the
simultaneous activation of many other cycles decreases
the likelihood of off-target effects. This conclusion is
Figure 4 Distribution of the size of off-target effects in the n = 3 network. Histograms of the size of off-target effects in n = 3 network
(Figure 3D) are plotted for two different parameter spaces. The y-axis on each plot represents the proportion of all parameter sets that
produced off-target effects in 5000 randomly selected parameter sets. The x-axis on each plot represents the size of an off-target effect in cycle
2 as a proportion of Y2T such that each value indicates a response that was at least as big as the given value but less than the next sequential
value. For example, a value of .30 indicates that the magnitude of the response was greater than or equal to .30 but less than 0.40. (A) The
majority of off-target effects in the original n = 3 parameter space (depicted in Figure 3H) were less than 0.30. (B) In contrast, the distribution of
the size of off-target effects in the restricted n = 3 parameter space (depicted in Figure 3I) was more uniform.
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based on a limited exploration of the parameter space
(due to the homogenous parameter selection used for
cycles 3 and greater) but is in agreement with a model
proposed by Kim et al. [8] that showed retroactivity (or
what they referred to as subsrate-dependent control) is
attenuated by the number of substrates available.
Off-target effects from retroactivity can propagate down
a non-targeted cascade
Our results suggest that, under appropriate conditions,
it is possible for a downstream perturbation from a tar-
geted inhibitor to transmit up a cascade resulting in a
detectable off-target effect near the top of another cas-
cade. Because signal amplification is an important cellu-
lar sensory mechanism [19], we next investigated
whether off-target effects from targeted inhibitors are
likely to amplify down a non-targeted cascade.
To test for downstream propagation of off-target
effects from cycle 2, we created an extended n = 3 net-
work by adding a 4th cycle activated by Y2* (Figure 2D).
If a change in the steady state concentration of Y4 and/
or Y4* occurred that was at least 0.10 of the total Y4
protein pool, then an off-target effect was considered to
have occurred in cycle 4. If an off-target effect occurred
in cycle 4 and the size of the response in cycle 4
exceeded the size of the response in cycle 2, then an
off-target effect with amplification was considered to
have occurred in cycle 4.
When the default parameter ranges defined in Table 1
were used for all cycles in the extended n = 3 network,
the percentage of off-targets in cycle 2 and cycle 4,
respectively, was 1.78% and 0.03%. We next tested the
extended n = 3 network using the restricted n = 3 para-
meter space (depicted in Figure 3I) for cycles 1 - 3 and
Figure 5 Varying a single parameter value can produce a large change in the off-target response. Stimulus response curves were plotted
for the n = 3 network using a randomly selected parameter set and a parameter set derived from a Xenopus model [18] (all parameters values
are listed in Table 2). For each parameter set, E2 and K3 were increased or decreased by 1 order of magnitude and the resulting stimulus
response curves were plotted. (A-B) The random parameter set produced an off-target effect in Y2 of 0.40 (data not shown) and in Y2* of 0.19.
(A) Increasing E2 from 32.56 to 325.61 substantially decreased the off-target effect in Y2*, while decreasing E2 to 3.26 increased the off-target
effect in Y2* to 0.27. (B) Increasing K3 from 0.04 to 0.41 reduced the response in Y2* below the detection threshold to 0.07, while decreasing K3
to 0.004 increased the off-target response to 0.26. (C-D) A second parameter set was derived from the literature using MAPK parameters from a
Xenopus model. This parameter set did not initially produce an off-target effect because the response in both Y2* and Y2 was 0.08, which was
below the detection threshold. (C) Increasing or decreasing E3 to 0.025 or 0.00025, respectively, from 0.0025 had no effect on the response to
the targeted inhibitor. (D) In contrast, increasing K3 from 0.25 to 2.5 eliminated the original response completely, while decreasing K3 from 0.25
to 0.025 produced a large off-target response of 0.60. Original parameter values prior to variation are indicated by ‡ on the plots (see also Table
2).
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the default parameter ranges from Table 1 for cycle 4.
In this partially restricted parameter space (depicted in
Additional File 3 Figure S4H), the percentage of off-tar-
get effects in cycle 2 and cycle 4 were 75.3% and 35.5%,
respectively, and amplification contributed to cycle 4
off-target effects in 23.3% of the sampled parameter sets
(representing more than half of the off-target effects in
the sampled parameter sets). The remaining off-target
effects in cycle 4 occurred in 12.2% of the sampled para-
meter sets and had a response size that was either atte-
nuated relative to cycle 2 or equal to the cycle 2
response (Table 4).
To identify the parameters that were most important
for amplifying an off-target effect from cycle 2 to cycle
4 in the extended n = 3 network, we performed a
numeric perturbation analysis (as previously described)
on the partially restricted parameter space depicted in
Additional File 3 Figure S4H. From these results, we
generated a new parameter space (Additional File 3 Fig-
ure S4I) which produced off-target effects of 45.3% and
67.4% in cycle 2 and cycle 4, respectively. Amplification
contributed to cycle 4 off-target effects in 61.9% of the
sampled parameter sets. The remaining off-target effects
in cycle 4 occurred in 5.5% of the sampled parameter
sets and had a response size that was either attenuated
relative to cycle 2 or equal to the cycle 2 response
(Table 4).
Discussion
We developed a computational model to test whether
targeted therapies, such as kinase inhibitors, can pro-
duce off-target effects in upstream pathways as a conse-
quence of retroactivity alone. Using a numeric
perturbation method, we identified specific conditions
(Figure 6) that favored the promotion of steady state
off-target effects via retroactivity when a targeted inhibi-
tor was applied to cycle n in a series of simple signaling
networks (Figure 2).
Our investigation considered only the effect of retro-
activity and targeted inhibitors on the individual motifs
we studied in the absence of genetic and/or other regu-
latory relationships. This allowed us to investigate
whether such motifs have the capacity to produce off-
target effects without regulatory feedback connections.
In addition, the present study only considered the steady
state response to a targeted therapy. The primary reason
we considered only steady state responses was because
it provided us with an objective measure that could be
used to compare the effect of a targeted inhibitor across
many different parameter sets. It is important to note
that the dynamics of a retroactive signaling process are
Table 2 Parameter sets used in stimulus response curves.
Random set Xenopus set
E1 4.87 0.1
E2 32.56 0.0025
E3 0.28 0.0025
E’1 0.05 0.1
E’2 1.26 0.00025
E’3 0.29 0.1
K1 5.07 100
K2 28.18 0.25
K3 0.04 0.25
K’1 66.34 100
K’2 9.33 0.25
K’3 0.59 0.25
P1 0.21 1
P2 3.43 1
P3 0.42 0.025
KB 0.05 0.0833
The two parameters sets used in Figure 5 are summarized in the table. The
Random set refers to a randomly selected parameter set and the Xenopus set
refers to a parameter set derived from a Xenopus MAPK model (Additional File
4). Bolded values represent the original parameter values varied in Figure 5.
Table 3 The percentage of off-target effects decreased as
the network size increased.
n Off Target Effects
3 73.9
vertical lateral
5 27.9 6.0
7 13.5 0.0
The n = 3 network’s restricted parameter space produced 73.9% off-target
effects. The n = 5 and n = 7 vertical case networks produced 27.9% and
13.5% off-target effects, respectively, using the same parameter space. In the
lateral case the drop was more dramatic with the n = 5 and n = 7 networks
producing 6% and 0% off-target effects, respectively. Parameter values used
in cycles 4, 5, 6 or 7 were homogenous with cycle 3. All percentages are out
of 5000 randomly selected parameter sets using the parameter space
depicted in Figure 3I.
Table 4 Off-target effects can amplify downstream of
cycle 2.
Cycle 2 Cycle 4
Cycles 1-3 with restricted ranges and cycle 4 with default ranges
% Off Target Effects 75.3 35.5
% Off Target Effects with Amplification – 23.4
% Off Target Effects without Amplification – 12.1
Cycles 1- 4 with restricted ranges
% Off Target Effects 45.3 67.4
% Off Target Effects with Amplification – 61.9
% Off Target Effects without Amplification – 5.5
To test for downstream propagation of off-target effects from cycle 2, the
extended n = 3 network was used. If an off-target effect occurred in cycle 4
and the size of the response in cycle 4 exceeded the size of the response in
cycle 2, then an off-target effect with amplification was reported for cycle 4.
First, the n = 3 restricted parameter space was used for cycles 1 - 3 and the
default parameter ranges from Table 1 were used for cycle 4 (Additional File 3
Figure S4H). Next, cycles 2 - 4 were further restricted to ranges which favor
off-target effect propagation from cycle 2 to 4 (Additional File 3 Figure S4I).
Values listed in the table are percentages out of 5000 randomly selected
parameter sets.
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likely to induce transient changes in the levels of key
signaling molecules. These transient changes, which are
not observable at steady state, may lead to important in
vivo responses.
It is also well known that the dynamics of signal trans-
duction networks can be modulated by important oscil-
latory behavior, for example, from the P53/MDM2
regulatory feedback loop [20,21]. Because we have not
considered transient dynamics, our approach cannot be
assumed to apply to all signaling networks. Nevertheless,
we expect conditions that favor the induction of off-tar-
get effects at steady state to also favor the induction of
detectable transient changes associated with the steady
state response. In fact, this is what we observed when
we plotted the time-course of the cycle 2 proteins with
the parameter sets used in Figure 5 (data not shown).
This work has led to very interesting and somewhat
surprising results. A major importance of this work is
that it did not investigate off-target effects related to a
specific therapeutic intervention. There are, however,
examples of targeted inhibitors of great clinical interest
that are involved in signaling motifs similar to the net-
work motifs we examined. The drug NSC 74859 [22],
for example, is a selective inhibitor that targets STAT3.
JAK is an upstream activator of both STAT3 and PI3K
[23], thus when NSC 74859 inhibits STAT3, JAK could
potentially facilitate the propagation off-target effects
due to retroactive signaling from STAT3 to PI3K. More-
over, the inhibitor GSK690693 [24] targets AKT and
could potentially give rise to a retroactive signal that
propagates upstream to a common activator of either
the MAPK or STAT3 cascades, generating off-target
effects in these pathways.
The binding affinity of the inhibitor for its target did
not play a substantial role in the promotion of off-target
effects in our model. Instead, the kinetics of the compo-
nent cycles in the network were more important for
increasing the likelihood of off-target effects (Figure 3
and Additional File 3 Figure S3, S4). In general, off-tar-
get effects were more likely to occur in the networks
studied when the targeted cycle n favored the deactiva-
tion reaction because the Vmax of the deactivation reac-
tion was larger than the Vmax of the activation reaction
and/or both enzymatic reactions in cycle n operated in
or near the zero order regime. Off-target effects were
also more likely when cycle 1 (the source of the shared
activator in our models) favored the activation reaction
and its kinase reaction operated in or near the zero
order regime.
If cycle 2’s cascade was extended to include cycle 4
(Figure 2D), which was activated by Y2*, off-target
effects were more likely to propagate to cycle 4 when
cycle 2 favored deactivation and cycle 4 favored activa-
tion. In cycle 2 this meant that the kinetics of the kinase
reaction were generally inefficient (operating in or near
the linear regime) and that the Vmax of the deactivation
reaction was generally larger than the Vmax of the acti-
vation reaction. Thus, off-target effects were promoted
when cycle 2 was “off” and not consuming significant
amounts of the shared upstream activator, Y1*.
Figure 6 A summary of conditions that favor off-target effects in the n = 3 and the extended n = 3 networks. The conditions that
promoted off-target effects in our model are summarized for two network types. Off-target effects in (A) the n = 3 network and (B) the
extended n = 3 network were favored when cycle 3 tended toward deactivation and cycle 1 tended toward activation. Off-target effects were
favored in cycle 4 of (B) the extended n = 3 network when cycle 2 tended toward deactivation and cycle 4 tended toward activation. Blue
arrows in a cycle indicate which Vmax is larger when off-target effects are favored. (C) A summary of the specific conditions in each cycle found
to favor off-target effects in the n = 3 network, in the extended n = 3 network, or in both networks is also provided.
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The results also indicate that off-target effects were
more likely when the total kinase to substrate and the
total phosphatase to substrate ratios in the inhibited
cycle (En and E’n, respectively) were less than 1. In the
n = 3 network, this meant that there was less total pro-
tein in cycle 1 than in cycle 3 because E3 < 1 implies
Y1T <Y3T. The reason for this is that the smaller the
Y1T/Y3T ratio, the stronger the sequestration of Y1* will
be. The impact of this ratio increases if cycle 3 favors
the deactivation reaction such that a large fraction of
Y3T is in the inactive Y3 form, promoting the binding of
Y3 to Y1*.
The immediate experimental implications of this result
is that, in the absence of kinetic information, the likeli-
hood of off-target effects may potentially be estimated
for a network configuration of this type (Figure 2A,C-D)
based on the ratio of the concentrations of components
in the inhibited cycle and the preceding cycle (using, for
example, proteomic or gene expression data). While this
ratio would not be an absolute predictor, the presence
of this condition would suggest an increased probability
of off-target effects.
In agreement with the work of other groups [8,9],
we found the probability of off-target effects attenu-
ated when the targeted cycle was near the bottom of a
long cascade or when there were many substrates
competing for a common upstream activator (Table
3). Our results also suggest that within physiologically
realistic parameter ranges, changing a single kinetic
parameter or species concentration by 1 order of mag-
nitude has the capacity to dramatically alter whether
an off-target effect occurs as a direct result of targeted
inhibition. It is also worth noting that, even though
we varied the normalized drug concentration over a
very large range, in general, the normalized inhibitor
concentration needed to change by only 2 orders of
magnitude to induce an off-target effect (see, for
example, Figure 5).
Conclusions
Off-target drug effects in vivo are typically attributed to
cross-talk arising from a feedback connection in a sig-
naling network or to non-specific interactions with
other proteins. In this work we have demonstrated that
off-target drug effects can also arise naturally from ret-
roactivity in a covalently modified signaling network.
This view of signaling challenges the widespread notion
that information in signaling cascades only flows from
the cell surface to the nucleus and, consequently, this
work has far reaching implications for targeted cancer
therapies.
A crucial finding of this work is that the kinetics
governing the covalently modified cycles in a signaling
network are likely to be far more important for propa-
gating an off-target effect due to retroactive signaling
than the binding affinity of the drug for the targeted
protein, which is a commonly optimized property in
drug development. Another particularly paramount
finding is that an off-target effect due to retroactive
signaling is more likely when the first cycle in a non-
inhibited cascade is “off” and essentially inactive. This
suggests that, in the motifs we studied, a targeted ther-
apy has the capacity to turn “on” an otherwise “off” tri-
butary cascade.
To emphasize, it is entirely possible for a branch of a
signaling network that is “off” to become activated or
“on” due to the inhibition of another protein in the net-
work based on retroactivity alone, suggesting an inher-
ent opportunity for negative therapeutic effects. Our
findings, therefore, have implications for somatic evolu-
tion in cancer and the onset of therapeutic resistance,
which has been widely reported for many targeted can-
cer therapeutics [25], most notably for the targeted inhi-
bition of BCR-ABL by imatinib [26]. Moreover, a single
mutation could conceivably give rise to a spontaneous
off-target effect without the need for any direct regula-
tory connections between the targeted protein and the
effected protein.
While our approach does not definitively establish that
the predicted responses will occur in vivo, our results
demonstrate that off-target effects are indeed possible in
the absence of direct regulatory relationships and sug-
gest that additional (and more specific) experimental
and theoretical investigations are warranted. A proper
characterization of a pathway’s structure is important
for identifying the optimal protein to target as well as
what concentration of the targeted therapy is required
to modulate the pathway in a safe and effective manner.
We believe our results strongly support the position
that such characterizations should consider retroactivity
as a potential source of off-target effects induced by
kinase inhibitors and other targeted therapies. This
work has also provided an initial roadmap for how to
assess the likelihood of off-target effects in a signaling
network.
Appendix A - Non-dimensionalization of the n = 3
network
In order to reduce the complexity of the networks stu-
died, model parameters were non-dimensionalized. The
following explains the non-dimensionalization of the n
= 3 network. The dimensionless parameters of the n = 5
and n = 7 vertical and lateral networks’ were obtained
in a similar manner.
The ODEs and conservation laws governing the n = 3
network (Figure 2C) at steady state are:
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d[Y∗1 ]
dt
= k1[C1] − a′1[Y∗i ][Ep1 ] + d′1[C′1]
− a2[Y2][Y∗1 ] + (d2 + k2)[C2]
− a3[Y3][Y∗1 ] + (d3 + k3)[C3] = 0
d[C1]
dt
= a1[Y1][Ek1 ] − (d1 + k1)[C1] = 0
d[C′1]
dt
= a′1[Y
∗
i ][Ep1 ] − (d′1 + k′1)[C′1] = 0
d[Y∗2 ]
dt
= −a′2[Y∗2][Ep2 ] + d′2[C′2] + k2[C2] = 0
d[C2]
dt
= a2[Y2][Y∗1 ] − (d2 + k2)[C2] = 0
d[C′2]
dt
= a′2[Y
∗
2 ][Ep2 ] − (d′2 + k′2)[C′2] = 0
d[Y∗3 ]
dt
= −a′3[Y∗3 ][Ep3 ] + d′3[C′3] + k3[C3]
− kon[Y∗3][D] + koff [CD] = 0
d[C3]
dt
= a3[Y3][Y∗1 ] − (d3 + k3)[C3] = 0
d[C′3]
dt
= a′3[Y
∗
3 ][Ep3 ] − (d′3 + k′3)[C′3] = 0
d[CD]
dt
= kon[Y∗3 ][D] − koff [CD] = 0
Y1T = [Y1] + [Y∗1 ] + [C1] + [C
′
1] + [C2] + [C3]
Y2T = [Y2] + [Y∗2 ] + [C2] + [C
′
2]
Y3T = [Y3] + [Y∗3 ] + [C3] + [C
′
3] + [CD]
Ek1T = [Ek1 ] + [C1]
Ep1T = [Ep1 ] + [C
′
1]
Ep2T = [Ep2 ] + [C
′
2]
Ep3T = [Ep3 ] + [C
′
3]
DT = [D] + [CD]
Dimensionless Parameters
Pi =
kiEkiT
k′iEpiT
=
Vmaxki
Vmaxpi
Ei =
EkiT
YiT
E’i =
EpiT
YiT
Ki =
di + ki
aiYiT
=
Kmki
YiT
K ′i =
d′i + k′i
a′iYiT
=
Kmpi
YiT
KB =
koff /kon
Y3T
(for n = 3)
KB =
koff /kon
YnT
(for all n)
I =
DT
Y3T
(for n = 3) I =
DT
YnT
(for alln)
where EkiT =
⎧⎪⎪⎨
⎪⎪⎩
i = 1,
i = 2, i = 3,
i > 3 (vertical),
i > 3 (lateral),
Ek1T
Y1T
Y(i−1)T
Y1T
Dimensionless Variables
yi =
[Yi]
YiT
y∗i =
[Y∗i ]
YiT
Algebraic rearrangement and substitution yield the
following dimensionless steady state equations:
(1) P1
y1
y1 + K1
− y
∗
1
y∗1 + K
′
1
= 0
(2)
−1 + y1 + y∗1
(
1 +
y2
K2
+
y3
K3
)
+E1
y1
y1 + K1
+ E′1
y∗1
y∗1 + K
′
1
= 0
(3) P2
y2y∗1
K2
− y
∗
2
y∗2 + K
′
2
= 0
(4)
−1 + y2
(
1 + E2
y∗1
K2
)
+ y∗2
+E′2
y∗2
y∗2 + K
′
2
= 0
(5) P3
y3y∗1
K3
− y
∗
3
y∗3 + K
′
3
= 0
(6)
−1 + y3(1 + E3 y
∗
1
K3
) + y∗3
+E′3
y∗3
y∗3 + K
′
3
+ I
y∗3
y∗3 + KB
= 0
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Additional material
Additional file 1: Mapping dimensionless parameters to
dimensional parameters. This file describes how randomly sampled
dimensionless parameter values were mapped to dimensional parameter
values prior to numeric simulation.
Additional file 2: Parameter space sampling to estimate the
probability of off-target effects. This file describes how the parameter
space of a network was sampled to provide an estimate of the
probability of off-target effects due to retroactivity alone.
Additional file 3: Additional analysis of the n = 3 and extended n =
3 networks. This file provides additional results from the numeric
perturbation analyses of the n = 3 and extended n = 3 networks.
Additional file 4: Xenopus MAPK Model Parameters [18,27,28]. This
file explains how the Xenopus model parameters listed in Table 2 were
derived.
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